151 related articles for article (PubMed ID: 15041274)
1. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels.
Saw J; Kereiakes DJ; Mahaffey KW; Applegate RJ; Braden GA; Brent BN; Brodie BR; Groce JB; Levine GN; Leya F; Moliterno DJ
Thromb Res; 2003; 112(5-6):301-6. PubMed ID: 15041274
[TBL] [Abstract][Full Text] [Related]
2. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test.
Silvain J; Beygui F; Ankri A; Bellemain-Appaix A; Pena A; Barthelemy O; Cayla G; Gallois V; Galier S; Costagliola D; Collet JP; Montalescot G
J Am Coll Cardiol; 2010 Feb; 55(7):617-25. PubMed ID: 20170785
[TBL] [Abstract][Full Text] [Related]
3. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
[TBL] [Abstract][Full Text] [Related]
4. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
Ma JM; Jackevicius CA; Yeo E
Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
[TBL] [Abstract][Full Text] [Related]
5. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
6. Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent.
Schaden E; Schober A; Hacker S; Spiss C; Chiari A; Kozek-Langenecker S
Blood Coagul Fibrinolysis; 2010 Apr; 21(3):256-61. PubMed ID: 20087172
[TBL] [Abstract][Full Text] [Related]
7. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
[TBL] [Abstract][Full Text] [Related]
8. Variability of plasma anti-Xa activities with different lots of enoxaparin.
Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
Ann Pharmacother; 2004 Apr; 38(4):563-8. PubMed ID: 14982983
[TBL] [Abstract][Full Text] [Related]
9. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
Hammerstingl C; Omran H; Tripp C; Poetzsch B
Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
[TBL] [Abstract][Full Text] [Related]
10. Dosage of enoxaparin among obese and renal impairment patients.
Bazinet A; Almanric K; Brunet C; Turcotte I; Martineau J; Caron S; Blais N; Lalonde L
Thromb Res; 2005; 116(1):41-50. PubMed ID: 15850607
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
[TBL] [Abstract][Full Text] [Related]
12. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
Montalescot G; Cohen M; Salette G; Desmet WJ; Macaya C; Aylward PE; Steg PG; White HD; Gallo R; Steinhubl SR;
Eur Heart J; 2008 Feb; 29(4):462-71. PubMed ID: 18276619
[TBL] [Abstract][Full Text] [Related]
13. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients.
Van PY; Cho SD; Underwood SJ; Morris MS; Watters JM; Schreiber MA
J Trauma; 2009 Jun; 66(6):1509-15; discussion 1515-7. PubMed ID: 19509608
[TBL] [Abstract][Full Text] [Related]
14. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability.
Kitchen S; Iampietro R; Woolley AM; Preston FE
Thromb Haemost; 1999 Oct; 82(4):1289-93. PubMed ID: 10544915
[TBL] [Abstract][Full Text] [Related]
15. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of enoxaparin, a low molecular weight heparin in the prevention of deep vein thrombosis in Nigerian patients after orthopaedic surgery.
Akanmu AS; Nnodu OE; Giwa SO; Salako LA; Akinsete I; Adebule GT; Adekoya-Cole TO; Odunubi OO
Afr J Med Med Sci; 2004 Dec; 33(4):335-40. PubMed ID: 15977441
[TBL] [Abstract][Full Text] [Related]
17. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study.
Moliterno DJ; Hermiller JB; Kereiakes DJ; Yow E; Applegate RJ; Braden GA; Dippel EJ; Furman MI; Grines CL; Kleiman NS; Levine GN; Mann T; Nair RN; Stine RA; Yacubov SJ; Tcheng JE;
J Am Coll Cardiol; 2003 Sep; 42(6):1132-9. PubMed ID: 13678943
[TBL] [Abstract][Full Text] [Related]
18. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
19. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
Frank RD; Brandenburg VM; Lanzmich R; Floege J
Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
[TBL] [Abstract][Full Text] [Related]
20. The use of a HEMOCHRON JR. HEMONOX point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures.
El Rouby S; Cohen M; Gonzales A; Hoppensteadt D; Lee T; Zucker ML; Khalid K; Laduca FM; Fareed J
J Thromb Thrombolysis; 2006 Apr; 21(2):137-45. PubMed ID: 16622609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
